
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aficamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Bayer AG
Deal Size : $162.0 million
Deal Type : Series D Financing
Bayer and RTW Investments Lead Series D in Chinese Biotech Ji Xing Pharmaceuticals
Details : The financing will enable the company to support Ji Xing Pharmaceuticals in the commercialization of JIXING’s pipeline assets in the areas of cardiovascular diseases and ophthalmology.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 06, 2024
Lead Product(s) : Aficamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Bayer AG
Deal Size : $162.0 million
Deal Type : Series D Financing
